Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

Part of paid clinical trials in Los Angeles, California.

Sponsor
Nuvation Bio Inc.
Study ID
NCT07703436
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Astrocytoma IDH Mutant Grade 2
  • Astrocytoma IDH Mutant Grade 3
  • Glioma
  • Grade 2 IDH1-mutant Glioma
  • Grade 3 IDH1-mutant Glioma
  • IDH1-mutant Glioma
  • Oligodendroglioma
  • Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Safusidenib — DRUG
    Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs.

Study Details

This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.

Key Dates

First listed
Jul 14, 2026
Start date
Mar 31, 2027
Status verified
Aug 2026
Primary completion
Sep 30, 2030
Completion
Mar 31, 2032

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Safusidenib
    Safusidenib 250 mg BID

Primary Outcome Measure

Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR) [ Time Frame: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
University of California, Los AngelesLos AngelesCalifornia90095
Quan Li
[email protected]
310-825-1416
Robert Chong, MD (PRINCIPAL_INVESTIGATOR)
University of California, San FranciscoSan FranciscoCalifornia94143
Neuro Onc New Patient Coordinator
[email protected]
415-353-2193
John De Groot, MD (PRINCIPAL_INVESTIGATOR)
Yale UniversityNew HavenConnecticut06510
Amy Rodrigues
[email protected]
[email protected]
Nicholas Blondin, MD (PRINCIPAL_INVESTIGATOR)
Indiana UniversityIndianapolisIndiana46202
NeuroOncology Clinical Trials
[email protected]
3179634823
Kathryn Nevel, MD (PRINCIPAL_INVESTIGATOR)
Rutgers Cancer InstituteNew BrunswickNew Jersey08901
Kasie Diorio
[email protected]
732-235-2465
Morana Vojnic, MD (PRINCIPAL_INVESTIGATOR)
Columbia University Medical CenterNew YorkNew York10032
Research Nurse Navigator
[email protected]
212-342-5162
Andrew Lassman, MD (PRINCIPAL_INVESTIGATOR)
NYU Langone HealthNew YorkNew York10016
Jose McFaline-Figueroa, MD
[email protected]
212-731-6267

Find similar trials in Los Angeles, CA

Nationwide
Brain cancer trialsOncology trialsNeuro-oncology trials
By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
University of California, Los Angeles· Los Angeles, CAUniversity of California, San Francisco· San Francisco, CAYale University· New Haven, CTIndiana University· Indianapolis, INRutgers Cancer Institute· New Brunswick, NJColumbia University Medical Center· New York, NY

Related Studies